ACADIA Pharmaceuticals Inc. (ACAD): Price and Financial Metrics

ACADIA Pharmaceuticals Inc. (ACAD): $14.64

-0.34 (-2.27%)

POWR Rating

Component Grades














  • Quality is the dimension where ACAD ranks best; there it ranks ahead of 88.23% of US stocks.
  • The strongest trend for ACAD is in Stability, which has been heading down over the past 179 days.
  • ACAD's current lowest rank is in the Momentum metric (where it is better than 12.28% of US stocks).

ACAD Stock Summary

  • For ACAD, its debt to operating expenses ratio is greater than that reported by merely 13.44% of US equities we're observing.
  • ACAD's price/sales ratio is 8.43; that's higher than the P/S ratio of 82.69% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.29 for Acadia Pharmaceuticals Inc; that's greater than it is for only 16.77% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Acadia Pharmaceuticals Inc, a group of peers worth examining would be WISA, PROG, CLPT, ERII, and RADA.
  • ACAD's SEC filings can be seen here. And to visit Acadia Pharmaceuticals Inc's official web site, go to

ACAD Valuation Summary

  • In comparison to the median Healthcare stock, ACAD's price/sales ratio is 60.53% higher, now standing at 6.1.
  • ACAD's price/earnings ratio has moved up 39.7 over the prior 210 months.
  • ACAD's EV/EBIT ratio has moved down 3.2 over the prior 210 months.

Below are key valuation metrics over time for ACAD.

Stock Date P/S P/B P/E EV/EBIT
ACAD 2021-08-31 6.1 5.0 -10.7 -10.0
ACAD 2021-08-30 5.9 4.8 -10.4 -9.6
ACAD 2021-08-27 5.9 4.9 -10.5 -9.7
ACAD 2021-08-26 5.8 4.7 -10.2 -9.4
ACAD 2021-08-25 6.0 4.9 -10.5 -9.8
ACAD 2021-08-24 5.9 4.8 -10.4 -9.6

ACAD Growth Metrics

    Its 3 year net income to common stockholders growth rate is now at -58.89%.
  • The 2 year price growth rate now stands at 184.94%.
  • Its 4 year cash and equivalents growth rate is now at 1.84%.
ACAD's revenue has moved up $390,844,000 over the prior 52 months.

The table below shows ACAD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 484.145 -125.66 -167.87
2021-09-30 474.394 -130.028 -191.536
2021-06-30 463.359 -135.757 -261.739
2021-03-31 458.241 -147.313 -260.009
2020-12-31 441.755 -136.166 -281.584
2020-09-30 419.074 -138.385 -267.86

ACAD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ACAD has a Quality Grade of C, ranking ahead of 66.5% of graded US stocks.
  • ACAD's asset turnover comes in at 0.606 -- ranking 51st of 682 Pharmaceutical Products stocks.
  • AKBA, PBYI, and DRRX are the stocks whose asset turnover ratios are most correlated with ACAD.

The table below shows ACAD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.606 0.980 -0.702
2021-03-31 0.593 0.979 -0.724
2020-12-31 0.573 0.977 -0.744
2020-09-30 0.543 0.974 -0.652
2020-06-30 0.515 0.972 -0.541
2020-03-31 0.531 0.969 -0.585

ACAD Price Target

For more insight on analysts targets of ACAD, see our ACAD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $25.53 Average Broker Recommendation 1.83 (Hold)

ACAD Stock Price Chart Interactive Chart >

Price chart for ACAD

ACAD Price/Volume Stats

Current price $14.64 52-week high $28.06
Prev. close $14.98 52-week low $12.24
Day low $14.60 Volume 2,365,000
Day high $15.25 Avg. volume 2,051,533
50-day MA $17.83 Dividend yield N/A
200-day MA $20.75 Market Cap 2.37B

ACADIA Pharmaceuticals Inc. (ACAD) Company Bio

Acadia Pharmaceuticals Inc is a biotechnology company which develops and commercializes biopharmaceutical products to address central nervous system disorders. The firm aims to discover small molecule drugs to address Parkinson's, Alzheimer's and schizophrenia. The company was founded in 1993 by Mark Brann, PhD., a professor at the University of Vermont, under the name Receptor Technologies. By 1997, the company established its headquarters in San Diego, California and changed its name to Acadia Pharmaceuticals Inc and currently employs over 400 people. Since 2015, Stephen R. Davis serves as Acadia’s Chief Executive Officer and member of the board of directors. Competition for Acadia includes Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S, and off-label branded and generic antipsychotics.

ACAD Latest News Stream

Event/Time News Detail
Loading, please wait...

ACAD Latest Social Stream

Loading social stream, please wait...

View Full ACAD Social Stream

Latest ACAD News From Around the Web

Below are the latest news stories about Acadia Pharmaceuticals Inc that investors may wish to consider to help them evaluate ACAD as an investment opportunity.

Acadia's NUPLAZID, FDA's Second Chance To Get Alzheimer's Right

Acadia (ACAD) has been suffering from the FDA's CRL beatdown of its poorly designed, overly aggressive NUPLAZID (pimavanserin) clinical trial. The FDA has been suffering from blowback on its overly broad and poorly conceived ADUHELM (aducanumab) approval in treatment of Alzheimer's disease [AD]. Acadia has revised and resubmitted its NUPLAZID...

Out of Ignorance on Seeking Alpha | February 22, 2022

Will Acadia Pharmaceuticals (ACAD) Report Negative Earnings Next Week? What You Should Know

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 21, 2022

The past year for ACADIA Pharmaceuticals (NASDAQ:ACAD) investors has not been profitable

ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) shareholders will doubtless be very grateful to see the share price up 45...

Yahoo | February 17, 2022

Acadia Pharmaceuticals Announces Resubmission of Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) to Treat Alzheimer’s Disease Psychosis

SAN DIEGO, February 16, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that it has resubmitted its supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP) to the U.S. Food and Drug Administration (FDA).

Yahoo | February 16, 2022

Here's How Much a $1000 Investment in Acadia Pharmaceuticals Made 10 Years Ago Would Be Worth Today

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Yahoo | February 16, 2022

Read More 'ACAD' Stories Here

ACAD Price Returns

1-mo -14.29%
3-mo -42.18%
6-mo -38.90%
1-year -44.06%
3-year -45.23%
5-year -48.20%
YTD -37.28%
2021 -56.34%
2020 24.96%
2019 164.56%
2018 -46.30%
2017 4.40%

Continue Researching ACAD

Here are a few links from around the web to help you further your research on Acadia Pharmaceuticals Inc's stock as an investment opportunity:

Acadia Pharmaceuticals Inc (ACAD) Stock Price | Nasdaq
Acadia Pharmaceuticals Inc (ACAD) Stock Quote, History and News - Yahoo Finance
Acadia Pharmaceuticals Inc (ACAD) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.616 seconds.